Molecular imaging signals new treatment protocol for kidney cancer

June 11, 2012

Research revealed at the Society of Nuclear Medicine's 2012 Annual Meeting explores treatment with a newly developed type of radioimmunotherapy used for treating a resistant form of kidney cancer. The agent is able to hone in on the disease, called clear cell renal carcinoma, and kill the cancer by delivering radiation directly to it. However, the study shows that its effectiveness could be diminished when used after another anti-cancer therapy.

The radioimmunotherapy highlighted in this study is radiolabeled monoclonal antibody girentuximab (also known as cG250), a potent anticancer therapy that delivers a precise and powerful dose of radiation just at the site of cancerous tissues. Theobjective of the study was to investigate the effect of the widely used (TKI) on the targeting of In-111-cG250 in clear cell renal .

"This research has important implications for future therapeutic regimens for patients with clear cell renal carcinoma," says Stijn Muselaers, M.D., lead physician of the study at Radboud University Nijmegen Medical Centre in Nijmegen, The Netherlands. "This study indicates that imaging and therapy of tumors with radiolabeled antibodies could be hampered in patients that are being treated with TKIs such as sorafenib. This informs clinicians about the most appropriate sequence of treatments for patients with clear cell renal carcinoma in order to improve the care and potential survival of these patients."

The tumor-seeking abilities of In-111-cG250 were tested in patients treated with another type of anti-cancer therapy called sorafenib,which interferes with the growth and spread of . Results of the study showed significantly lower tumor targeting of In-111-cG250 in patients after treatment with the sorafenib. The reason for this is that sorafenib prevents cG250 from targeting its receptor in the tumors, indicating that radioisotope-labeled cG250-based therapy might not be as effective as it would be if used alone.

For this study, 15 patients with a renal mass scheduled for surgery were recruited. Of these, 13 had clear cell renal carcinoma and ten of the participants received treatment with sorafenib. All participants were imaged with a molecular imaging method called immunoSPECT using In-111-cG250 at the beginning of the study and after the ten subjects completed treatment with sorafenib. Scans showed remarkably lower targeting of In-111-cG250 to tumors in patients who received sorafenib. These results suggest that imaging and radioimmunotherapy with cG250 drug compounds should be prescribed before a patient begins treatment with or similar TKIs.

The U.S. National Cancer Institute estimates that in 2012, approximately 64,770 new cases will be diagnosed and 13,570 deaths will occur in America due to . There are two major forms of the disease, including renal cell carcinoma and renal pelvis carcinoma. Clear cell renal carcinoma, which gets its name from the clear liquid gel called cytoplasm inside the cells, is a subtype of thought to be caused in part by genetic mutations. This cancer develops in the tubules involved in the filtration of blood and waste products.

Explore further: Cancer-seeking 'smart bombs' target kidney cancer cells

Related Stories

Cancer-seeking 'smart bombs' target kidney cancer cells

June 6, 2011
Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. Patients with progressive kidney cancer receiving up to three doses of the therapy ...

FDA clears Pfizer drug for advanced kidney cancer

January 27, 2012
(AP) -- The Food and Drug Administration has approved a new Pfizer drug for patients with advanced kidney cancer that has spread to other parts of the body despite treatment with at least one previous drug.

Patients treated with sunitinib and sorafenib respond to flu vaccine

June 28, 2011
Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journal ...

Recommended for you

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

Scientists restore tumor-fighting structure to mutated breast cancer proteins

September 20, 2017
Scientists at the Virginia Tech Carilion Research Institute have successfully determined the full architecture of the breast cancer susceptibility protein (BRCA1) for the first time. This three-dimensional information provides ...

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

New clinical trial explores combining immunotherapy and radiation for sarcoma patients

September 20, 2017
University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to ...

Researchers identify new target, develop new drug for cancer therapies

September 20, 2017
Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to ...

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.